Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has announced that a second patient enrolled in the ACCENT trial has recorded a confirmed complete response (CR). This finding follows the announcement earlier this week of a separate patient who achieved a pathological CR in the trial.

A confirmed complete response is a formal designation of response where there is a complete disappearance of all tumour lesions that is maintained for >2 months.

This is a rare outcome in advanced pancreatic cancer where the disease has spread to other parts of the body.

Amplia CEO and MD Dr Chris Burns commented:

“To see a second complete response in the ACCENT trial is really wonderful news, particularly given how rare these are observed in advanced pancreatic cancer. Along with the pathological CR announced earlier in the week, this outcome further demonstrates the promising activity narmafotinib, on top of standard-of-care, is showing in pancreatic cancer.”

The ACCENT trial is evaluating the Company’s best-in-class FAK inhibitor narmafotinib in combination with chemotherapy in advanced pancreatic cancer.

Second Complete Response Recorded in ACCENT Trial